Matthias Weckesser

Muenster, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications

Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.

Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.

Journal: European journal of nuclear medicine and molecular imaging
Published: May 19, 2025

Determination of the optimal imaging protocol for [18F]PSMA-PET-CT for the detection of bone metastases in prostate cancer patients.

Determination of the optimal imaging protocol for [18F]PSMA-PET-CT for the detection of bone metastases in prostate cancer patients.

Journal: Nuklearmedizin. Nuclear medicine
Published: July 12, 2024

Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [18F]F-PSMA 1007 PET.

Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [18F]F-PSMA 1007 PET.

Journal: Cancers
Published: August 27, 2022

Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.

Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.

Journal: Leukemia
Published: June 20, 2022

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA.

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA.

Journal: European journal of nuclear medicine and molecular imaging
Published: October 13, 2021

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging.

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging.

Journal: Annals of nuclear medicine
Published: August 11, 2021

Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis.

Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis.

Journal: Cancers
Published: July 04, 2021

Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy.

Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy.

Journal: Theranostics
Published: March 08, 2021

Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions.

Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions.

Journal: Annals of nuclear medicine
Published: February 25, 2021

Fluorodeoxyglucose F 18 for the Assessment of Acute Intestinal Graft-versus-Host Disease and Prediction of Response to Immunosuppressive Therapy.

Fluorodeoxyglucose F 18 for the Assessment of Acute Intestinal Graft-versus-Host Disease and Prediction of Response to Immunosuppressive Therapy.

Journal: Transplantation and cellular therapy
Published: February 21, 2021

18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD).

18F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD).

Journal: BMC cancer
Published: February 06, 2021

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management.

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management.

Journal: European journal of nuclear medicine and molecular imaging
Published: January 06, 2021
Showing 1-12 of 66

Last Updated: 09/26/2026